Lifesciences | Natick, Mass.
Naveris Raises Extended Series A to Total $19m for Early Detection Blood Tests of HPV and Other Viral-Related Cancers
Naveris, a molecular diagnostics healthcare company focused on novel diagnostic technologies for early detection of virus-related cancers, closed an extension of its Series A round led by Gurnet Point Capital bringing total company funding to over $19 million to date. Funds will be used to make their lead product NavDx® more accessible to patients to generate more data and integrate it into treatment guidelines, continue product development and advance the company’s pipeline of other viral-related cancer detection tests. [Full story]